The HSP (Heroin Signature Program) is one essential component of the DEA’s Intelligence Program to identify trends in heroin trafficking and distribution in the United States. The objective of the program is to identify and quantify the chemical components of heroin seized at U.S. ports of entry (POE), all non-POE...

Since 2009, Drug Enforcement Administration (DEA) reporting from the Los Angeles Field Division (LAFD) has explored drug-related mortality in the LAFD area of responsibility (AOR), which includes the State of Nevada. In 2019, LAFD personnel reviewed post-mortem toxicology records from the period between 2015 and 2018. These records show that...

DEA's Philadelphia Division conducted a review of laboratory analyzed drug seizures for Pennsylvania. The results of analyzing this data formed the basis for estimating the level of drugs present in Pennsylvania and highlights trends in drug availability.

DEA's revised and updated drug fact sheet about vaping and marijuana concentrates - what are they, what their origin is, what are the common street names for vaping and marijuana concentrates, what do vapes and various concentrates look like, how they are used/abused, what their effect of their use on...

DEA's revised and updated drug fact sheet about the class of drugs known as benzodiazepines (tranquilizers) - what are they, what their origin is, what are the common street names for these drugs, what do they look like, how they are abused, what their effect is on the mind and...

This document is an internal Drug Enforcement Administration quality system document for latent print examination. The effective period of the document is May 4, 2020 to August 18, 2022 and it is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the...

Drugs of Abuse delivers clear, scientific information about drugs in a factual, straightforward way. With the information in this guide, parents and caregivers can help their children make smart choices and avoid the consequences of drug abuse. This publication covers topics including the Controlled Substances Act and introduces drug classes...

The Drug Enforcement Administration is adjusting the 2020 aggregate production quotas for certain controlled substances in schedule II of the Controlled Substances Act and the assessment of annual needs for the list I chemicals ephedrine and pseudoephedrine. This increase is in response to the current nationwide COVID-19 public health emergency...

The flow of fentanyl into the United States in 2019 is more diverse compared to the start of the fentanyl crisis in 2014, with new source countries and new transit countries emerging as significant trafficking nodes. This is exacerbating the already multi-faceted fentanyl crisis by introducing additional source countries into...

Statement of Thomas Prevoznik Deputy Assistant Administrator Diversion Control Division Drug Enforcement Administration U.S. Department of Justice Before the Subcommittee on Health House Committee on Energy and Commerce U.S. House of Representatives at a hearing entitled “Combatting an epidemic: legislation to help patients with substance use disorders” presented March 3...